News Center
Diabetes medication Sitagliptin Phosphate Monohydrate 654671-77-9
【Catalog Number】AP2401
【CAS #】654671-77-9
【Molecular Formula】C16H20F6N5O6P
【Molecular Weight】523.32
Alias |
7-[(3R) -3-amino-1-oxo-4- (2,4,5-trifluorophenyl) butyl] -5,6,7,8-tetrahydro-3-trifluoro Methyl-1,2,4-triazolo [4,3-a] pyrazine phosphate monohydrate |
Catalog Number |
AP2401 |
CAS # |
654671-77-9 |
Molecular Formula |
C16H20F6N5O6P |
Molecular Weight |
523.32 |
Structural Formula |
|
Product Introduction CAS 654671-77-9 US-DMF No. 29226
|
Sitagliptin phosphate monohydrate, the English name is Sitagliptin Phosphate Monohydrate, and the American Chemical Abstracts Registration Number is cas 654671-77-9. Sitagliptin phosphate monohydrate (cas 654671-77-9) is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which controls blood glucose levels by protecting endogenous incretin and enhancing its effect. Glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) are incretins released against dietary intake. GLP-1 and GIP can increase insulin synthesis and release from islet β cells through intracellular signaling pathways. GLP-1 can also reduce glucagon secretion from islet α cells and reduce liver glucose production. However, both GLP-1 and GIP are rapidly metabolized by DPP-4, resulting in a loss of their insulinotropic effects. This medicine inhibits the degradation of incretin by DPP-4, so it can enhance the functions of GLP-1 and GIP, increase the release of insulin and reduce the glucagon level in the circulation (this effect is glucose-dependent). This drug selectively inhibits DPP-4 and has no inhibitory activity on DPP-8 or DPP-9. Can be used for the treatment of type 2 diabetes. |
VIWIT 沪ICP备12014533号-2